In comparison, TIGIT mAb-treated mice exhibit higher frequencies of tumour-infiltrating CD8+ T cells expressing IL2/TNF-α/IFN-γ and CD4+ T cells expressing IL2, without altering the ratio of memory CD4+ T cells [8,9]. This evidence concerns the gene CD8A and neoplasm.